Discontinuation of Semaglutide Therapy for Obesity Management
Open accessAbstract
This cohort study examines the risk of and baseline variables associated with discontinuation of semaglutide treatment for obesity management among individuals in Denmark.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Early discontinuation of semaglutide for weight loss is linked to low-income areas, mental health issues, other comorbidities and younger age.
“Our own unpublished data suggest that early discontinuation of semaglutide for weight loss is linked to low‐income areas, mental health issues, other comorbidities and younger age. 38”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Schmidt, M., Schmidt, S. A. J., Adelborg, K., Sundbøll, J., Laugesen, K., Ehrenstein, V., & Sørensen, H. T. (2019) · Clinical Epidemiology · doi:10.2147/clep.s179083 · Cited by 1,406 · see citing works
Self-citationWilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128 · see citing works
Grenard, J. L., Munjas, B. A., Adams, J. L., Suttorp, M., Maglione, M., McGlynn, E. A., & Gellad, W. F. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-011-1704-y · Cited by 635 · see citing works
Rodriguez, P. J., Zhang, V., Gratzl, S., Do, D., Goodwin Cartwright, B., Baker, C., Gluckman, T. J., Stucky, N., & Emanuel, E. J. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.57349 · Cited by 374 · see citing works
GLP-1 receptor agonist discontinuation among patients with obesity and/or type 2 diabetes
Do, D., Lee, T., Peasah, S. K., Good, C. B., Inneh, A., & Patel, U. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.13172 · Cited by 218 · see citing works
West, S., Scragg, J., Aveyard, P., Oke, J. L., Willis, L., Haffner, S. J. P., Knight, H., Wang, D., Morrow, S., Heath, L., et al. (2026) · BMJ · doi:10.1136/bmj-2025-085304 · Cited by 174 · see citing works
Taipale, H. T., Taylor, M., Lähteenvuo, M., Mittendorfer-Rutz, E., Tanskanen, A. J., & Tiihonen, J. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(26)00014-3 · Cited by 23 · see citing works
Sørensen, M. S., Pottegård, A., Andersen, N. E., Thomsen, R. W., & Lundby, C. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16222 · Cited by 18 · see citing works
Self-citationGraabæk, T., Nguyen, N. T., Sørensen, M. S., & Lundby, C. (2025) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70069 · Cited by 11 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Beyond Drugs or Surgery: Precision and Equity in Obesity Care
Varghese, R. T., Petridis, S. F., Kapoor, N., Varghese, C. V., & Bernal‐Mizrachi, E. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71450
- Authors
- Mailhac, A., Pedersen, L., Petersen, I., Pottegård, A., Sørensen, H. T., & Thomsen, R. W.
- Affiliations
- Department of Clinical Epidemiology and Center for Population Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
- Aarhus University (DK)
- University of Southern Denmark (DK)
- Venue
- JAMA Network Open
- Publisher
- American Medical Association (AMA)
- Published
- 2026-08-28
- Volume
- 9
- Issue
- 8
- Pages
- e2631371
- ISSN
- 2574-3805 (ISSN-L)
- PMC
- PMC13525464
- OpenAlex
- W7204599018
- Cited by
- 1
- References
- 9
- Citations by year
- 2026: 1
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- JAMA Network Open (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- semaglutide, obesity treatment, treatment discontinuation, GLP-1 receptor agonists, weight loss, predictors of discontinuation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
